R&D Trends

ArQule, Beryllium collaborate

Wednesday, May 6, 2015 02:44 PM

ArQule, a Woburn, Mass.-based biotechnology company, and Beryllium Discovery, a company using target-centric platforms to provide research services and collaborations to commercial and academic partners, have formed a collaborative R&D agreement to identify and unlock the therapeutic potential of small molecule compounds by combining ArQule’s chemistry and drug development experience with Beryllium’s discovery platforms. The Beryllium platforms integrate structure-guided drug discovery, biophysics and cell biology.

More... »


Shire, Foundation Fighting Blindness ink research agreement for rare pediatric eye disease

Monday, May 4, 2015 01:01 PM

Shire and the Foundation Fighting Blindness, a national nonprofit organization focused on the entire spectrum of retinal diseases, have formed a new agreement to further research for a novel treatment for autosomal dominant retinitis pigmentosa (adRP), a rare genetic disease that usually first occurs in late childhood or adolescence and is followed by the progressive loss of peripheral vision. There currently are no approved treatment options for adRP.

More... »


NIH awards $17.9 million for blinding diseases research

Friday, May 1, 2015 12:58 PM

The National Eye Institute (NEI) has awarded five projects funds to develop new technology to noninvasively image cells of the eye as part of its Audacious Goals Initiative. NEI has committed $3.8 million to the projects in 2015 and up to $17.9 million over the next five years, pending the availability of funds. NEI is part of the National Institutes of Health.

More... »

AstraZeneca, Celgene collaborate on serious blood cancers

Friday, May 1, 2015 12:51 PM

AstraZeneca and MedImmune, AZ’s global biologics R&D arm, have entered into an exclusive collaboration agreement with Celgene for the development and commercialization of MEDI4736 across a range of blood cancers including non-Hodgkin's lymphoma, myelodysplastic syndromes and multiple myeloma.

More... »

Calico, Buck Institute ink agreement to research the biology of aging

Thursday, April 30, 2015 12:02 PM

Calico, a Google-founded R&D company focused on aging research and therapeutics, and the Buck Institute for Research on Aging, based in California, have partnered to support research into longevity and age-related diseases. Financial terms have not been disclosed.

More... »

Report: Pipeline advancements, asset acquisitions fueled biotech R&D spend in 2014

Wednesday, April 29, 2015 12:17 PM

The combined spend on R&D for the peer group of 35 mid-cap biotech companies increased by nearly $2 billion to reach a total of $9.7 billion in 2014, primarily thanks to top spenders Regeneron and Vertex, according to research and consulting firm GlobalData.

More... »

OncoGenex regains rights to custirsen from Teva

Wednesday, April 29, 2015 12:15 PM

OncoGenex Pharmaceuticals has announced its wholly owned subsidiary, OncoGenex Technologies, executed a termination agreement with Teva under which OncoGenex will regain rights to custirsen, an investigational compound currently in phase III clinical development as a treatment for prostate and lung cancers. This transfer of rights occurs in connection with the termination of the 2009 collaboration agreement between OncoGenex and Teva.

More... »

Resverlogix, Shenzhen Hepalink Pharma ink $450M deal

Wednesday, April 29, 2015 12:12 PM

Resverlogix, a clinical stage cardiovascular company based in Canada, and China-based Shenzhen Hepalink Pharmaceutical have formed a combination licensing and equity arrangement for RVX-208 in China, Hong Kong, Taiwan and Macau. The completion of the transaction remains subject to execution of a definitive stock purchase agreement and license agreement.

More... »

uBiome launches Clinical Lab

Wednesday, April 29, 2015 12:10 PM

San Francisco-based uBiome has launched a CLIA-regulated clinical laboratory to provide clinical tests based on its unique microbial assays.

More... »

Accenture, Oracle expand Life Sciences Cloud for R&D

Friday, April 24, 2015 01:14 PM

Accenture, a global management consulting, technology services and outsourcing company, has expanded the Accenture Life Sciences Cloud for R&D, powered by Oracle, with the addition of enhanced clinical data management capabilities. This enables life sciences companies to generate high-quality, reliable and statistically sound data from clinical trials to reduce the time, effort and cost needed to take drugs from development to market.

More... »

CenterWatch
CWWeekly

May 26

inVentiv Health aims to help sponsors prepare for new E.U. regulations on observational studies

ACRP partners with CRO Analytics to measure investigative sites' views of clinical trial quality

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs